Glomerulonephritis
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.
Subtype terms (6)
More specific conditions that are subtypes of Glomerulonephritis in the MeSH hierarchy.
- Anti-Glomerular Basement Membrane Disease
5 drugs (1 approved, 4 experimental)
- Glomerulonephritis, IGA
81 drugs (46 approved, 35 experimental)
- Glomerulonephritis, Membranoproliferative
16 drugs (10 approved, 6 experimental)
- Glomerulonephritis, Membranous
36 drugs (23 approved, 13 experimental)
- Glomerulosclerosis, Focal Segmental
57 drugs (34 approved, 23 experimental)
- Lupus Nephritis
128 drugs (52 approved, 76 experimental)
Drugs by status
Approved for this indication (4)
Phase 4 trials (9)
Phase 3 trials (12)
Phase 2 trials (28)
Phase 1 trials (7)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (21)
- Novartis
- Mallinckrodt
- Huazhong University of Science and Technology
- University of London
- Kagawa University
- Ohio State University
- University of Oslo
- University of Oulu
- Columbia University
- Peking University
- Dalian Medical University
- Jiao Tong University
- University of Lyon
- Magna Graecia University
- Osaka City General Hospital
- Tianjin TongRenTang Group Co., Ltd.
- Shantou University
- China Medical University
- People's Liberation Army of China
- LinkDoc Technology (Beijing) Co. Ltd.
- Jemincare
Organization Involved with Phase 3 Indications (45)
- Roche
- Sanofi
- Hamad Medical Corporation
- La Jolla Pharmaceutical Company
- Ajou University
- Azienda Ospedaliera Brotzu
- Azienda Ospedaliera Universitaria Policlinico
- D'Annunzio University of Chieti–Pescara
- Korea University
- Kyung Hee University
- Melbourne Health
- Ilsan Hospital
- Radboud University
- Seoul National University
- University of Melbourne
- University of Messina
- University of Milan
- University of Pavia
- University of Pisa
- University of Alberta
- University of Bari
- University of Bern
- University of Bologna
- Yonsei University
- Assiut University
- Chonbuk National University
- University of Modena and Reggio Emilia
- Hanmi Pharmaceutical
- Humanitas University
- National Taiwan University
- +15 more
Organization Involved with Phase 2 Indications (28)
- Achillion Pharmaceuticals
- Daiichi Sankyo
- MorphoSys
- Genentech
- Wyeth
- Alexion
- Alnylam Pharmaceuticals
- GlaxoSmithKline
- Apellis Pharmaceuticals, Inc.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- A.O. Ospedale Papa Giovanni XXIII
- Region Skane
- Hospital Universitari de Bellvitge
- University of Washington
- University of Leicester
- University of Toronto
- Mayo Clinic
- Badalona Hospital Germans Trias i Pujol
- Universidad de los Andes
- Sun Yat-Sen University
- Mario Negri Institute
- University of Barcelona
- Metronomia Clinical Research GMBH
- Q2 solutions
- IQVIA
- Goldfinch Bio, Inc.
- Travere Therapeutics, Inc.
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (4)